JP2010513259A - 広汎性発達障害の治療 - Google Patents

広汎性発達障害の治療 Download PDF

Info

Publication number
JP2010513259A
JP2010513259A JP2009540868A JP2009540868A JP2010513259A JP 2010513259 A JP2010513259 A JP 2010513259A JP 2009540868 A JP2009540868 A JP 2009540868A JP 2009540868 A JP2009540868 A JP 2009540868A JP 2010513259 A JP2010513259 A JP 2010513259A
Authority
JP
Japan
Prior art keywords
formulation
composition
nutritional product
use according
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009540868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513259A5 (cg-RX-API-DMAC7.html
Inventor
アンドリュー ショーン リンチ
ケリー ルイーザ ハンブルトン
スティーブン リーランド スミス
Original Assignee
エス・エイチ・エス インターナショナル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エス・エイチ・エス インターナショナル リミテッド filed Critical エス・エイチ・エス インターナショナル リミテッド
Publication of JP2010513259A publication Critical patent/JP2010513259A/ja
Publication of JP2010513259A5 publication Critical patent/JP2010513259A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009540868A 2006-12-14 2007-12-14 広汎性発達障害の治療 Pending JP2010513259A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0624879.3A GB0624879D0 (en) 2006-12-14 2006-12-14 Treatment of pervasive development disorders
PCT/GB2007/004815 WO2008071991A1 (en) 2006-12-14 2007-12-14 Treatment of pervasive developmental disorders

Publications (2)

Publication Number Publication Date
JP2010513259A true JP2010513259A (ja) 2010-04-30
JP2010513259A5 JP2010513259A5 (cg-RX-API-DMAC7.html) 2012-03-22

Family

ID=37712065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009540868A Pending JP2010513259A (ja) 2006-12-14 2007-12-14 広汎性発達障害の治療

Country Status (16)

Country Link
US (1) US20100055073A1 (cg-RX-API-DMAC7.html)
EP (1) EP2091526B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010513259A (cg-RX-API-DMAC7.html)
AT (1) ATE507827T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007331276A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0720230B8 (cg-RX-API-DMAC7.html)
CA (1) CA2672738A1 (cg-RX-API-DMAC7.html)
DE (1) DE602007014400D1 (cg-RX-API-DMAC7.html)
ES (1) ES2365469T3 (cg-RX-API-DMAC7.html)
GB (1) GB0624879D0 (cg-RX-API-DMAC7.html)
IL (1) IL199340A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009006459A (cg-RX-API-DMAC7.html)
PL (1) PL2091526T3 (cg-RX-API-DMAC7.html)
RU (1) RU2441652C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008071991A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200904240B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137944A1 (en) * 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
MX2013003636A (es) 2013-03-27 2014-09-29 Palsgaard Ind De Mexico S De R L De C V Complemento alimenticio para personas con trisomia 21, transtorno del espectro autista y/o transtorno por deficit de atencion con o sin hiperactividad.
WO2015002527A1 (en) * 2013-07-05 2015-01-08 N.V. Nutricia Amino acid composition for use in the treatment of a pdd
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
US11541068B2 (en) 2017-05-24 2023-01-03 Glycom A/S HMO compositions and methods for reducing autism spectrum disorder symptoms
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
WO2022258873A1 (es) * 2021-06-09 2022-12-15 Hospital Sant Joan De Deu Combinación nutracéutica y su uso para el tratamiento de trastornos neurológicos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414238A (en) * 1981-12-24 1983-11-08 Cutter Laboratories, Inc. Liquid elemental diet
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
SE510813C2 (sv) * 1997-12-08 1999-06-28 Arla Ekonomisk Foerening Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen
US20020155170A1 (en) * 2000-11-30 2002-10-24 Walsh William John Nutrient supplements and methods for treating autism and for preventing the onset of autism
CN1255413C (zh) * 2001-06-14 2006-05-10 阿克佐诺贝尔公司 作为ampa受体正性调节剂的(吡啶并/噻吩并)-[f]-氧杂吖庚因-5-酮衍生物
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012065992; JOURNAL OR FAMILY HEALTH CARE VOL.12, NO.2, 2002, P.34-38 *

Also Published As

Publication number Publication date
RU2009126763A (ru) 2011-01-20
EP2091526A1 (en) 2009-08-26
US20100055073A1 (en) 2010-03-04
ES2365469T3 (es) 2011-10-06
MX2009006459A (es) 2009-11-23
ATE507827T1 (de) 2011-05-15
ZA200904240B (en) 2010-08-25
DE602007014400D1 (de) 2011-06-16
EP2091526B1 (en) 2011-05-04
PL2091526T3 (pl) 2011-10-31
BRPI0720230A2 (pt) 2013-12-24
IL199340A0 (en) 2010-03-28
WO2008071991A1 (en) 2008-06-19
AU2007331276A2 (en) 2011-03-31
AU2007331276A1 (en) 2008-06-19
BRPI0720230B1 (pt) 2020-12-15
CA2672738A1 (en) 2008-06-19
GB0624879D0 (en) 2007-01-24
RU2441652C2 (ru) 2012-02-10
BRPI0720230B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
EP3010521B1 (en) Synbiotic composition for treatment of infections in allergic patients
AU2019261707B8 (en) Prebiotics for reducing the risk of obesity later in life
US20230131859A1 (en) Bioconversion of oleuropein
RU2441652C2 (ru) Лечение общих расстройств развития
US20230045437A1 (en) Compositions Comprising Probiotic and Prebiotic Components and Mineral Salts, with Lactoferrin
TW201004574A (en) A nutritional composition with free amino acids and structured lipids
US20080085268A1 (en) Use of lactobacillus farciminis for the prevention or treatment of digestive pathologies
JP2023110015A (ja) オレウロペインの生物変換
CN118201501A (zh) 用于改善婴儿微生物群的营养组合物
HK1186628A (en) Compositions and methods for augmenting kidney function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130315

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130819